Loading…
Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results....
Saved in:
| Published in: | Medicinski arhiv 2016-10, Vol.70 (5), p.342-347 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c309t-bf88be297ebdbcdf71df1a736c242ad1163102bfd6ed9385abd1d8488db115563 |
|---|---|
| cites | |
| container_end_page | 347 |
| container_issue | 5 |
| container_start_page | 342 |
| container_title | Medicinski arhiv |
| container_volume | 70 |
| creator | Sofo-Hafizovic, Alma Chikha, Adisa Gojak, Refet Hadzimesic, Emina Suljovic |
| description | Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.
achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.
A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.
Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X
. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p |
| doi_str_mv | 10.5455/medarh.2016.70.342-347 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5136440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4228670121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-bf88be297ebdbcdf71df1a736c242ad1163102bfd6ed9385abd1d8488db115563</originalsourceid><addsrcrecordid>eNpdkV9rFDEUxYModq1-hRIQwZfZ5s8kmbwUdN3qwhZFW_AtZCZ3OlNmJmMys3a_fbNsLerDJVxy7uGe-0PojJKlyIU478HZ0CwZoXKpyJLnLOO5eoYWVBcyE1rS52hBuCAZ1frnCXoV4x0hQiumX6ITprTOmeYL9Ht9PwaIsfUD3ny_PL-6uaIXTLzD3wK4tpp8wJPH100AyPZgA_4xh127sx32Nf7U1vUcAW9tuAX8Ea-g6_B234-N7y1uBzw1gDd9Pw--aqD3qQ123ON1sK_Ri9p2Ed48vqfo5nJ9vfqSbb9-3qw-bLOKEz1lZV0UJTCtoHRl5WpFXU2t4rJiObOOUskpYWXtJDjNC2FLR12RF4UrKRVC8lN0cfQd5zLdrIJhCrYzY2h7G_bG29b8-zO0jbn1OyMol3lOksH7R4Pgf80QJ9O3sUpB7QB-joYWgrJ07oIm6dv_pHd-DkOKl1ScScUkP2wkj6oq-BgD1E_LUGIObM2RrTmwNYqYxDaVSoNnf0d5GvsDkz8AzE6isw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1832672636</pqid></control><display><type>article</type><title>Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Sofo-Hafizovic, Alma ; Chikha, Adisa ; Gojak, Refet ; Hadzimesic, Emina Suljovic</creator><creatorcontrib>Sofo-Hafizovic, Alma ; Chikha, Adisa ; Gojak, Refet ; Hadzimesic, Emina Suljovic</creatorcontrib><description>Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.
achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.
A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.
Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X
. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p<0,0005 X
. Significantly longer three-year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X
. Clinical and immunohistochemical factors showed a significant impact to three-year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three-year survival.
expression MUM1 >25% has the greatest impact on the disease outcome - three-year survival.</description><identifier>ISSN: 0350-199X</identifier><identifier>EISSN: 1986-5961</identifier><identifier>DOI: 10.5455/medarh.2016.70.342-347</identifier><identifier>PMID: 27994293</identifier><language>eng</language><publisher>Bosnia and Herzegovina: Academy of Medical Sciences of Bosnia and Herzegovina</publisher><subject>Adolescent ; Adult ; Aged ; Female ; Humans ; Immunotherapy ; Interferon Regulatory Factors - metabolism ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - mortality ; Male ; Middle Aged ; Original Paper ; Prospective Studies ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult</subject><ispartof>Medicinski arhiv, 2016-10, Vol.70 (5), p.342-347</ispartof><rights>Copyright Academy of Medical Sciences of Bosnia and Herzegovina 2016</rights><rights>Copyright: © 2016 Alma Sofo-Hafizovic, Adisa Chikha, Refet Gojak, and Emina Suljovic Hadzimesic 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-bf88be297ebdbcdf71df1a736c242ad1163102bfd6ed9385abd1d8488db115563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1832672636/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1832672636?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27994293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sofo-Hafizovic, Alma</creatorcontrib><creatorcontrib>Chikha, Adisa</creatorcontrib><creatorcontrib>Gojak, Refet</creatorcontrib><creatorcontrib>Hadzimesic, Emina Suljovic</creatorcontrib><title>Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era</title><title>Medicinski arhiv</title><addtitle>Med Arch</addtitle><description>Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.
achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.
A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.
Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X
. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p<0,0005 X
. Significantly longer three-year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X
. Clinical and immunohistochemical factors showed a significant impact to three-year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three-year survival.
expression MUM1 >25% has the greatest impact on the disease outcome - three-year survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon Regulatory Factors - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0350-199X</issn><issn>1986-5961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkV9rFDEUxYModq1-hRIQwZfZ5s8kmbwUdN3qwhZFW_AtZCZ3OlNmJmMys3a_fbNsLerDJVxy7uGe-0PojJKlyIU478HZ0CwZoXKpyJLnLOO5eoYWVBcyE1rS52hBuCAZ1frnCXoV4x0hQiumX6ITprTOmeYL9Ht9PwaIsfUD3ny_PL-6uaIXTLzD3wK4tpp8wJPH100AyPZgA_4xh127sx32Nf7U1vUcAW9tuAX8Ea-g6_B234-N7y1uBzw1gDd9Pw--aqD3qQ123ON1sK_Ri9p2Ed48vqfo5nJ9vfqSbb9-3qw-bLOKEz1lZV0UJTCtoHRl5WpFXU2t4rJiObOOUskpYWXtJDjNC2FLR12RF4UrKRVC8lN0cfQd5zLdrIJhCrYzY2h7G_bG29b8-zO0jbn1OyMol3lOksH7R4Pgf80QJ9O3sUpB7QB-joYWgrJ07oIm6dv_pHd-DkOKl1ScScUkP2wkj6oq-BgD1E_LUGIObM2RrTmwNYqYxDaVSoNnf0d5GvsDkz8AzE6isw</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Sofo-Hafizovic, Alma</creator><creator>Chikha, Adisa</creator><creator>Gojak, Refet</creator><creator>Hadzimesic, Emina Suljovic</creator><general>Academy of Medical Sciences of Bosnia and Herzegovina</general><general>AVICENA, d.o.o., Sarajevo</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161001</creationdate><title>Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era</title><author>Sofo-Hafizovic, Alma ; Chikha, Adisa ; Gojak, Refet ; Hadzimesic, Emina Suljovic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-bf88be297ebdbcdf71df1a736c242ad1163102bfd6ed9385abd1d8488db115563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon Regulatory Factors - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sofo-Hafizovic, Alma</creatorcontrib><creatorcontrib>Chikha, Adisa</creatorcontrib><creatorcontrib>Gojak, Refet</creatorcontrib><creatorcontrib>Hadzimesic, Emina Suljovic</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicinski arhiv</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sofo-Hafizovic, Alma</au><au>Chikha, Adisa</au><au>Gojak, Refet</au><au>Hadzimesic, Emina Suljovic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era</atitle><jtitle>Medicinski arhiv</jtitle><addtitle>Med Arch</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>70</volume><issue>5</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>0350-199X</issn><eissn>1986-5961</eissn><abstract>Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.
achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.
A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.
Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X
. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p<0,0005 X
. Significantly longer three-year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X
. Clinical and immunohistochemical factors showed a significant impact to three-year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three-year survival.
expression MUM1 >25% has the greatest impact on the disease outcome - three-year survival.</abstract><cop>Bosnia and Herzegovina</cop><pub>Academy of Medical Sciences of Bosnia and Herzegovina</pub><pmid>27994293</pmid><doi>10.5455/medarh.2016.70.342-347</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0350-199X |
| ispartof | Medicinski arhiv, 2016-10, Vol.70 (5), p.342-347 |
| issn | 0350-199X 1986-5961 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5136440 |
| source | ProQuest - Publicly Available Content Database; PubMed Central |
| subjects | Adolescent Adult Aged Female Humans Immunotherapy Interferon Regulatory Factors - metabolism Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Original Paper Prospective Studies Retrospective Studies Survival Rate Treatment Outcome Young Adult |
| title | Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A49%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20IRF/MUM1%3E25%25%20Predictor%20to%20Three-year%20Survival%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20in%20the%20Immunochemotherapy%20Era&rft.jtitle=Medicinski%20arhiv&rft.au=Sofo-Hafizovic,%20Alma&rft.date=2016-10-01&rft.volume=70&rft.issue=5&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=0350-199X&rft.eissn=1986-5961&rft_id=info:doi/10.5455/medarh.2016.70.342-347&rft_dat=%3Cproquest_pubme%3E4228670121%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c309t-bf88be297ebdbcdf71df1a736c242ad1163102bfd6ed9385abd1d8488db115563%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1832672636&rft_id=info:pmid/27994293&rfr_iscdi=true |